These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 23805906

  • 1. Biosimilars: the paradox of sharing the same pharmacological action without full chemical identity.
    Pani L, Montilla S, Pimpinella G, Bertini Malgarini R.
    Expert Opin Biol Ther; 2013 Oct; 13(10):1343-6. PubMed ID: 23805906
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Biosimilars].
    Krämer I.
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [Abstract] [Full Text] [Related]

  • 5. [The story of biosimilars--chance or threat?].
    Woroń J, Kocić I.
    Pol Merkur Lekarski; 2014 Nov; 37(221):311-5. PubMed ID: 25546996
    [Abstract] [Full Text] [Related]

  • 6. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
    Gonçalves J, Araújo F, Cutolo M, Fonseca JE.
    Clin Exp Rheumatol; 2016 Nov; 34(4):698-705. PubMed ID: 27383278
    [Abstract] [Full Text] [Related]

  • 7. [Biosimilars: regulatory status for approval].
    Herrero Ambrosio A.
    Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
    [Abstract] [Full Text] [Related]

  • 8. Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.
    Schiestl M, Zabransky M, Sörgel F.
    Drug Des Devel Ther; 2017 Mar; 11():1509-1515. PubMed ID: 28553082
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Biosimilars--opportunity or threat?].
    Swierkot J.
    Wiad Lek; 2013 Mar; 66(2 Pt 2):200-5. PubMed ID: 25775818
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The US approach to biosimilars: the long-awaited FDA approval pathway.
    Calvo B, Zuñiga L.
    BioDrugs; 2012 Dec 01; 26(6):357-61. PubMed ID: 23030677
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Biosimilars in oncology: from development to clinical practice.
    Rak Tkaczuk KH, Jacobs IA.
    Semin Oncol; 2014 Apr 01; 41 Suppl 3():S3-S12. PubMed ID: 24767633
    [Abstract] [Full Text] [Related]

  • 20. Comparability and biosimilarity: considerations for the healthcare provider.
    Lee JF, Litten JB, Grampp G.
    Curr Med Res Opin; 2012 Jun 01; 28(6):1053-8. PubMed ID: 22519391
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.